Costly drug may save money in severe childbirth bleeding, but study cut short
NCT ID NCT02900690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the costs of treating severe postpartum hemorrhage with a drug called NovoSeven compared to standard care. Researchers wanted to see if the higher drug cost could be offset by avoiding expensive procedures. The trial was terminated early and included 84 women with severe bleeding after childbirth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant activated factor VII (NovoSeven)
- What this could lead to
- If successful, it could show whether using NovoSeven is cost-effective for severe bleeding after childbirth, potentially guiding hospital policies.
- What could go wrong
- The trial was terminated early, so results are limited. It only looked at costs, not whether NovoSeven improves survival or reduces complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH CARE COST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes
Nîmes, Gard, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.